Ligand Pharma (LGND) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Cantor Fitzgerald Reiterate Hold Following Ligand Pharma's (LGND) Strong Q1
May 13, 2015 7:23 AM EDTCantor Fitzgerald reiterate a Hold rating on Ligand Pharma (NASDAQ: LGND), and raise the price target to $86.00 (from $82.00), following a strong 1Q. LGND reported revenues of $14.6M, and an adjusted non-GAAP EPS of $0.33. Coming out ahead of FactSet consensus of $13.5M revenue and $0.27 EPS.... More
Ligand Pharma (LGND) PT Lifted to $127 at Roth Capital Following Q1 and as Pipeline Expands
May 11, 2015 11:34 AM EDTRoth Capital analyst Joseph Pantginis reiterated a Buy rating and boosted his price target on Ligand Pharma (NASDAQ: LGND) to $127.00 (from $116.00) following Q1 results.
LGND reported non-GAAP EPS of $0.33 vs. consensus of $0.27. LGND reported total revenues of $14.602 million vs. our estimate of $13.48 million and consensus... More
